Furthermore, the multi-specific DARPin® molecule, MP0250, was shown to strongly neutralize VEGF and HGF causing a significant reduction in the number of vessels and was defined as a novel combination drug for treatment of multiple myeloma patients [228]. This evidence concerns the gene HGF and plasma cell myeloma.